One of the factors that presumably plays a role in glaucoma manifestation is TGF-β
2. Studies have demonstrated that approximately 50% of patients with POAG have significantly increased levels of this cytokine in the AH.
7 8 9 10 Based on this, numerous studies have been undertaken to elucidate the effects of TGF-β
2 with respect to extracellular matrix (ECM) modifications in the TM, using human TM cell cultures.
11 12 Physiological studies, using the human anterior chamber (AC) perfusion system, have shown that perfusion with TGF-β
2 significantly reduces outflow facility,
13 and ultrastructural evaluation of the perfused material has revealed an increase of ECM underneath the inner wall of SC. Meanwhile, biochemical and molecular in vitro investigations have shown that TGF-β
2 is a potent activator of ECM component synthesis as well as of the expression of ECM degradation regulators. Among the proteins shown to be TGF-β
2 responsive were fibronectin (FN), an integral constituent of basement membranes (BM), tissue-type transglutaminase (tTgase), an enzyme cross-linking ECM to undegradable complexes
11 and plasminogen activator inhibitor (PAI)-1, a factor inhibiting matrix metalloproteinase (MMP) activation.
11 12 These data indicate that TGF-β
2 has the ability to activate the synthesis of ECM material and inhibit ECM degradation via PAI-1, resulting in an accumulation of ECM. However, to get insights into the composition of this material and the regulatory mechanisms and pathways involved, as well as to test other possible glaucoma-promoting factors, further molecular and morphologic investigations are essential.